Imbruvica Sales for Follicular Lymphoma across the US, Japan, and Five Major EU Markets, 2017-2026 - ResearchAndMarkets.com

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Jul 12, 2019 09:23 am
DUBLIN -- 

The "Imbruvica" report has been added to ResearchAndMarkets.com's offering.

Imbruvica (ibrutinib; AbbVie/Johnson & Johnson) is an oral small molecule inhibitor of Bruton's tyrosine kinase (BTK). BTK is part of the B-cell receptor signaling pathway, which promotes cell proliferation, adhesion, and survival in many B-cell malignancies. Imbruvica has been shown to inhibit these actions and induce apoptosis in malignant B-cells in preclinical models.

Imbruvica is not expected to receive approval for the treatment of diffuse large B-cell lymphoma (DLBCL) after failing to meet the primary endpoint of improved progression-free survival (PFS) in the Phase III PHOENIX trial (ClinicalTrials.gov identifier: NCT01855750) for non-germinal center B-cell (GCB) DLBCL patients.

However, AbbVie and Johnson & Johnson indicate that efficacy was seen in an unspecified subpopulation of patients, signaling that future development in this indication is possible. Potential approval, even in a small subgroup within the non-GCB subtype, would help to fill an unmet need as these patients typically have a worse prognosis and do not respond well to standard R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. However, Imbruvica's outlook will remain poor in DLBCL without clarity on the targeted patient subgroup or data to confirm efficacy.

Key Topics Covered:

OVERVIEW

Drug Overview

Product Profiles

Imbruvica: Chronic lymphocytic leukemia (CLL)

Imbruvica: NHL: Follicular lymphoma (FL)

Imbruvica: NHL: Diffuse large B-cell lymphoma (DLBCL)

Imbruvica: NHL: Mantle cell lymphoma (MCL)

LIST OF FIGURES

Figure 1: The authors drug assessment summary of Imbruvica for CLL

Figure 2: Imbruvica sales for CLL across the US, Japan, and five major EU markets, by country, 2017-26

Figure 3: Imbruvica for follicular lymphoma - SWOT analysis

Figure 4: The authors drug assessment summary of Imbruvica for follicular lymphoma

Figure 5: Imbruvica sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017-26

Figure 6: Imbruvica for diffuse large B-cell lymphoma - SWOT analysis

Figure 7: The authors drug assessment summary for Imbruvica in diffuse large B-cell lymphoma

Figure 8: Imbruvica for mantle cell lymphoma - SWOT analysis

Figure 9: The authors drug assessment summary of Imbruvica in mantle cell lymphoma

LIST OF TABLES

Table 1: Imbruvica drug profile

Table 2: Approval history of Imbruvica for CLL in the US, Japan, and five major EU markets

Table 3: Trials of Imbruvica for CLL

Table 4: Imbruvica for CLL - SWOT analysis

Table 5: Imbruvica drug profile

Table 6: Imbruvica ongoing pivotal trial in follicular lymphoma

Table 7: Imbruvica clinical trial data in follicular lymphoma

Table 8: Imbruvica sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017-26

Table 9: Imbruvica drug profile

Table 10: Imbruvica pivotal trial data in diffuse large B-cell lymphoma

Table 11: Early-phase data for Imbruvica in diffuse large B-cell lymphoma

Table 12: Imbruvica drug profile

Table 13: Imbruvica pivotal trial data in mantle cell lymphoma

Table 14: Imbruvica late-phase trial data in mantle cell lymphoma

Table 15: Imbruvica ongoing late-phase clinical trials in mantle cell lymphoma

For more information about this report visit https://www.researchandmarkets.com/r/p3zepp

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).